Skip to content

US · LQDA · MEDICAL - PHARMACEUTICALS

Liquidia Corporation (LQDA) intrinsic value and stock valuation

$54.43as of 2026-11-21 · Mkt cap 7.93B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Liquidia Corporation DCF and intrinsic value

InvestorsCraft values LQDA with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from LQDA’s statements →

Liquidia Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Pharmaceuticals Morrisville, NC 27560 liquidia.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$158.3M+192.5% 5y CAGRd
20162025
Net income
-$-68.92M
20162025
Free cash flow
-$-40.02M
20162025
Total equity
$44.8M-8.8% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$158.3M$14M$17.5M$15.9M$12.9M
Operating income-$-51.38M-$-121.29M-$-73.38M-$-38.77M-$-33.8M
Net income-$-68.92M-$-130.39M-$-78.5M-$-41.02M-$-34.58M
EPSd-$-800.84K-$-1.66M-$-1.21M-$-672.9K-$-696.05K
Operating cash flow-$-35.69M-$-93.42M-$-41.56M-$-28.59M-$-34.03M
Capital expenditure-$-4.34M-$-4.95M-$-1.29M-$-590K-$-110K
Free cash flow-$-40.02M-$-98.37M-$-42.85M-$-29.18M-$-34.14M
Total assets$327.9M$230.3M$118.3M$129.2M$93.7M
Total debt$197.9M$122.4M$49.5M$24.5M$16.1M
Net debt$7.25M-$-54.09M-$-34.14M-$-68.82M-$-41.41M
Total equity$44.8M$77.3M$47.3M$90.4M$65.3M
Cash and short-term investments$190.7M$176.5M$83.7M$93.3M$57.5M
Income statement
20252024202320222021
Revenue$158.3M$14M$17.5M$15.9M$12.9M
Cost of revenue$13.2M$5.88M$2.89M$2.86M$3.02M
Gross profit$145.1M$8.12M$14.6M$13.1M$9.83M
Research and development expenses$39.3M$47.8M$43.2M$19.4M$20.5M
Selling, general and administrative expenses$157.2M$81.6M$44.7M$32.4M$23.1M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$196.5M$129.4M$88M$51.9M$43.6M
Cost and expenses$209.7M$135.3M$90.9M$54.7M$46.7M
Interest income$6.62M$7.65M$3.47M$1.09M$30K
Interest expense$24.2M$12.5M$6.27M$2.34M$760K
Depreciation and amortization$1.53M$2.2M$2.18M$3.65M$5.61M
Ebitda-$-43.22M-$-115.71M-$-70.05M-$-35.03M-$-28.2M
Operating income-$-51.38M-$-121.29M-$-73.38M-$-38.77M-$-33.8M
Total other income/expenses, net-$-17.55M-$-9.1M-$-5.12M-$-2.25M-$-780K
Income before tax-$-68.92M-$-130.39M-$-78.5M-$-41.02M-$-34.58M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-68.92M-$-130.39M-$-78.5M-$-41.02M-$-34.58M
Weighted average shares outstanding$86.1M$78.7M$65M$61M$49.7M
Weighted average diluted shares outstanding$86.1M$78.7M$65M$61M$49.7M
Balance sheet
20252024202320222021
Cash and short-term investments$190.7M$176.5M$83.7M$93.3M$57.5M
Net receivables$54.1M$2.72M$4.06M$5.02M$2.99M
Inventory$0.00$240K$0.00$0.00$0.00
Total current assets$190.7M$185.1M$89.9M$99.8M$61.3M
Property, plant and equipment, net$0.00$12.5M$6.18M$6.25M$7.43M
Goodwill and intangible assets$6.86M$7.06M$7.33M$7.63M$8.29M
Long-term investments$3.5M$0.00$0.00$0.00$0.00
Total non-current assets$137.3M$45.2M$28.4M$29.4M$32.5M
Total assets$327.9M$230.3M$118.3M$129.2M$93.7M
Accounts payable$3.68M$4.69M$1.4M$2.2M$1.07M
Short-term debt$58.9M$18.4M$3.75M$1.08M$1.09M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$135.8M$41.8M$18.6M$8.8M$7.33M
Long-term debt$139M$104M$45.8M$23.4M$15M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$147.4M$111.3M$52.5M$30M$21.1M
Capital lease obligations$6.59M$7M$3.5M$4.58M$5.67M
Total liabilities$283.2M$153M$71M$38.8M$28.5M
Common stock$90K$90K$70K$60K$50K
Retained earnings-$-626.31M-$-559.49M-$-429.1M-$-350.6M-$-309.58M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$44.8M$77.3M$47.3M$90.4M$65.3M
Total investments$3.5M$0.00$0.00$0.00$0.00
Total debt$197.9M$122.4M$49.5M$24.5M$16.1M
Net debt$7.25M-$-54.09M-$-34.14M-$-68.82M-$-41.41M
Cash flow statement
20252024202320222021
Net income-$-68.92M-$-130.39M-$-78.5M-$-41.02M-$-34.58M
Depreciation and amortization$1.53M$2.2M$2.18M$3.65M$5.61M
Stock-based compensation$29.5M$18.8M$10.1M$9.3M$6.75M
Change in working capital-$-24.18M-$-4.79M$5.87M-$-2.16M-$-12.38M
Accounts receivable-$-51.37M$1.34M$960K-$-2.03M-$-2.99M
Inventory-$-22.99M-$-240K$0.00$0.00$0.00
Accounts payable-$-2.59M$2.33M-$-1.15M$810K-$-7.56M
Net cash provided by operating activities-$-35.69M-$-93.42M-$-41.56M-$-28.59M-$-34.03M
Investments in property, plant and equipment-$-4.34M-$-4.95M-$-1.29M-$-590K-$-110K
Acquisitions, net$0.00$0.00$0.00$10K$0.00
Net cash used for investing activities-$-6.34M-$-8.44M-$-11.29M-$-590K-$-110K
Common stock issued$4.82M$138.6M$24.2M$54.5M$21.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$59.7M$194.7M$43.3M$65M$26.3M
Net change in cash$14.2M$92.8M-$-9.6M$35.8M-$-7.82M
Cash at end of period$190.7M$176.5M$83.7M$93.3M$57.5M
Operating cash flow-$-35.69M-$-93.42M-$-41.56M-$-28.59M-$-34.03M
Capital expenditure-$-4.34M-$-4.95M-$-1.29M-$-590K-$-110K
Free cash flow-$-40.02M-$-98.37M-$-42.85M-$-29.18M-$-34.14M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Liquidia Corporation

        Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

        CEO
        Roger A. Jeffs
        Employees
        216
        Beta
        0.55

        Explore

        Frequently asked questions

        What is the intrinsic value of Liquidia Corporation (LQDA)?

        Liquidia Corporation (LQDA) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is LQDA undervalued?

        LQDA trades at a price of $54.43 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.